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Objectives: We assessed the impact of MALDITOF-MS on the timeliness of optimal antimicrobial therapy 
through a parallel-arm randomised controlled trial in two hospitals in Vietnam. 
Methods: We recruited patients with a pathogen (bacterial or fungal) cultured from a normally sterile 
sample. Samples were randomly assigned (1:1) to identification by MALDITOF-MS or conventional diag- 
nostics. The primary outcome was the proportion on optimal antimicrobial therapy within 24 h of posi- 
tive culture, determined by a blinded independent review committee. Trial registered at ClinicalTrials.gov 
(NCT02306330). 
Results: Among 1005 randomised patients, pathogens were isolated from 628 (326 intervention, 302 con- 
trol), with 377 excluded as likely contaminants or discharged/died before positive culture. Most isolates 
were cultured from blood (421/628, 67.0%). The proportion receiving optimal antimicrobial therapy within 
24 h (the primary outcome) or 48 h of growth was not significantly different between MALDITOF-MS and 
control arms (135/326, 41.4% vs 120/302, 39.7%; Adjusted Odds ration (AOR) 1.17, p = 0.40 and 151/326, 
46.3% vs 141/302, 46.7%; AOR 1.05 p = 0.79, respectively). 
Conclusions: MALDITOF-MS, in the absence of an antimicrobial stewardship programme, did not improve 
the proportion on optimal antimicrobial therapy at 24 or 48 h after first growth in a lower-middle income 
setting with high rates of antibiotic resistance. 
© 2019 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Introduction 
High quality laboratory diagnostics play an important role 
in the management of infectious diseases. 1 , 2 Low- and middle- 
income countries (LMICs) often lack the resources for these. 
The consequence is limited knowledge of bacterial epidemiol- 
ogy and susceptibility, exacerbating inappropriate antibiotics use 
https://doi.org/10.1016/j.jinf.2019.03.010 
0163-4453/© 2019 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license. 
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and impacting on both antimicrobial resistance (AMR) and patient 
outcomes. 
Recognising this, investment in hospital laboratory infrastruc- 
ture and capacity building in LMICs has attracted international 
attention. 3 –5 Efficient use of limited available resources is needed 
to develop optimal laboratory capacity, avoid inappropriate use 
of antibiotics and improve patient outcomes. 6 Novel technologies 
have been developed to improve identification and susceptibility 
testing results, but many are expensive 1 , 7 and developed in and 
for high income countries 8 but are now being introduced in LMIC 
laboratories. Systematic evaluation of these is important, espe- 
cially in resource constrained settings, to show impact on clinical 
decision-making and patient care. 
Matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDITOF-MS) accurately identifies cultured bacte- 
ria and fungi within minutes. 9 , 10 Whilst the hardware is expensive 
(approximately 250,0 0 0 USD) it has very low per assay costs (1-1.5 
USD/sample) and requires minimal skills. 9 –11 Reagents have long 
expiry dates, unlike traditional biochemical identification systems 
(leading to regular use of expired reagents is common in LMICs). 12 
Thus MALDITOF-MS has potential to improve microbiological diag- 
nostics in LMICs. 
Previous studies in high-income settings, where MALDITOF has 
been combined with an antimicrobial stewardship programme 
(ASP), have shown clinical impact on reduced time to optimal an- 
tibiotic therapy, 13 , 14 increased proportion of appropriate antibiotic 
treatment after culture positivity 15 and reduced length of hospital 
stay. 14 , 16 –18 
To date no randomised controlled trials have been reported 
exploring the benefit of MALDITOF-MS compared with conven- 
tional microbiology in relation to clinical endpoints, nor have there 
been any studies of its clinical (as opposed to diagnostic) utility 
in LMICs. We aimed to determine whether MALDITOF-MS reduced 
the time to optimal antibiotic therapy compared to conventional 
microbiological identification in patients with confirmed infection. 
Materials and Methods 
Study design and participants 
A parallel arm randomised controlled trial was conducted in 2 
tertiary infectious diseases hospitals in Vietnam: the National Hos- 
pital for Tropical Diseases (NHTD) in Hanoi and the Hospital for 
Tropical Diseases (HTD) in Ho Chi Minh City. Both have ISO15189 
accredited microbiology laboratories. Positive blood cultures or as- 
pirates from sterile compartments (cerebrospinal fluid (CSF), deep 
abscesses, joint fluid, peritoneal fluid, pleural fluid or deep tissue 
biopsies) were randomised. Patients with at least one pathogenic 
bacteria or fungus cultured from such samples were recruited, pa- 
tients whose cultures showed contamination were not recruited 
as optimal therapy for such patients would depend on the clini- 
cal picture rather than the blood culture result. Patients were not 
recruited if at the time of randomisation they already had an eli- 
gible sample processed during the same hospital admission. 
Microbiological methods 
Clinical specimens were collected and cultured according to 
standard practice. Blood culture bottles (aerobic) were incubated 
for up to five days in an automated system (Bactec, Becton- 
Dickinson, USA). Other samples were incubated on media allowing 
growth of aerobic, anaerobic and fastidious organisms and checked 
daily. Positive specimens were randomly allocated to identification 
by either MALDITOF-MS (Microflex LT/SH, Bruker, Germany, library 
DB4613) or conventional diagnostics. For the MALDITOF-MS arm, 
positive blood culture media or colonies from plates were sub- 
Control
N=510
MALDITOF
N=495
Analysis populaon N=302
6 unclassified:
5 Likely HAI in ICU
1 No appropriate sensivies
Total Paents Randomised:
N= 1005
169 Excluded: 
Contaminant = 153
Discharged before sample posive = 16
208 Excluded:
Contaminant = 189
Discharged before sample posive = 19
Analysis populaon N=326a
3 unclassified: 
3 Likely HAI in ICU
Fig. 1. Trial flow. 
a 2 patients randomised to MALDITOF had identification by routine methods. They 
were analysed as per their randomisation arm (i.e. included in MALDITOF group). 
cultured onto blood agar until growth could be observed. (Sup- 
plementary Fig. 1 ) Colonies were then analysed by MALDITOF-MS 
twice daily, a result was considered positive identification if it gave 
a score ≥2.00. In the control arm, methods for identification in- 
cluded: Gram-staining, API test strips, VITEK2 (bioMérieux, Marcy 
l’Étoile, France) and other tests as per standard operating proce- 
dures. All media were commercially sourced. 
Randomization and masking 
Randomisation was 1:1 by a web based randomization pro- 
gram using a random variable block length of 4 or 6, with strat- 
ification by hospital and specimen type (blood vs. other). When 
an eligible specimen showed growth, the technician entered pa- 
tient and specimen code into the randomization program. The di- 
agnostic pipeline allocation was then generated and logged. All 
subsequent positive eligible specimens from that patient were as- 
signed to the same arm. Patients were recruited when the sample 
grew a pathogen. In HTD only this followed consent of the partic- 
ipant or legal representative. Samples that yielded organisms not 
considered pathogens (e.g. coagulase-negative staphylococci, diph- 
theroids, viridans group streptococci in the absence of a matching 
clinical syndrome) were not included. Treating physicians were not 
informed of the allocated arm. 
Procedures 
Clinical and microbiological data were collected prospectively 
onto a Case Record Form (CRF) and checked for accuracy by re- 
search staff. At least 24 h following delivery of the written report 
to the ward, the research team asked the clinical team if this had 
changed management and if not, why not. 
No other changes were made to routine hospital procedures 
for communication of culture results to clinical teams. This in- 
volved direct reporting of Gram-stains and positive culture results 
by phone followed by issue of a written report through the inter- 
nal postal system. No antimicrobial stewardship intervention was 
involved in the study. Hospital staff had access to a variety of in- 
ternational and national guidelines. 
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Outcomes 
The primary outcome was the proportion of patients on opti- 
mal antimicrobial treatment within 24 h of positive culture (first 
observed growth of an eligible specimen). Optimal antimicrobial 
treatment was defined as treatment using any drug to which the 
isolate showed in vitro susceptibility (using AST results from the 
same agent or by proxy according to CLSI guidelines) and had 
known clinical susceptibility, but not including unnecessarily broad 
spectrum regimens. The decision on optimal therapy was made 
by an independent review committee, blinded to the diagnostic 
arm. The committee reviewed the admission and discharge diag- 
nosis, the antimicrobials used during the admission and the full 
microbiology results. The committee were asked to determine the 
following: presence of optimal antimicrobial therapy at 24 h and 
at 48 h (secondary endpoint), or at any point during hospital stay. 
If therapy was not optimal at 24 h the reasons were grouped into: 
too broad, organism not covered, and ‘other’. Examples of ‘too 
broad therapy’ would include: use of a carbapenem for treatment 
of confirmed meningitis or sepsis due to Streptococcus suis or 
Streptococcus pneumoniae or non-ESBL producing, cephalosporin 
susceptible Enterobacteriaceae ; use of a combination of ß-lactam 
and another agent for treatment of Enterobacteriaceae susceptible 
to the ß-lactam etc . Inter-reviewer discrepancies were resolved by 
discussion of the case and review of international guidelines. If the 
committee considered the organism was not the only reason for 
antimicrobial therapy a decision of ‘unclassifiable’ was recorded. 
Statistical analysis 
We expected the proportion of patients on optimal therapy 
within 24 h to increase from 40% (conventional diagnostics) to 60% 
(MALDITOF-MS). 15 To detect this with 90% power at the 2-sided 
significance level of 5%, requires a total sample size of 260. To al- 
low sufficient power for a subgroup analysis in blood cultures for 
each hospital separately, the target enrolment was 280 patients re- 
cruited at the slower recruiting hospital. 
The statistical analyses were predefined in an analysis plan. For 
the primary outcome we used a logistic regression model of the 
primary outcome depending on arm, with additional adjustment 
for the first specimen type (blood vs. other) and study site. As 
a conservative measure, subjects with an ‘unclassifiable’ primary 
outcome were labelled as ‘non-optimal’, as were subjects that were 
discharged or died within 24 h unless optimal therapy had been 
started before death/discharge. Subgroup analyses and secondary 
outcome of optimal therapy within 48 h of positive culture were 
performed in the same way as for the whole population. Analyses 
were performed using R (Version 3.4.0). P values below 0.05 were 
considered significant (two-sided). Further details available in sup- 
plementary material (statistics analysis plan). 
Ethics 
Eligible patients received written information about the study, 
informing them of its purpose, procedures, their right to refuse 
participation and how to get more information or withdraw. Any 
patient who requested not to be enrolled had their specimens la- 
belled accordingly and diagnostics as per routine practice. 
The institutional review board (IRB) in the National Hospital 
for Tropical Diseases (77/HDDD-NDTU) approved the study without 
the need for individual patient consent. The IRB in the Hospital for 
Tropical Diseases (16-HDDD-QD) required all patients (or legal rep- 
resentatives) to be seen by study staff, informed of the study, and 
give written consent before participation. The study was also ap- 
proved by the Oxford Tropical Research Ethics Committee (55-14) 
and registered at ClinicalTrials.gov (NCT02306330). 
Results 
Study Population 
The trial recruited between 1st December 2014 and 15th Jan- 
uary 2016. The study was stopped when the sample size for the 
primary outcome was exceeded. 1005 patients with a positive ster- 
ile site culture were randomized. In accordance with the proto- 
col, the 342 cultured bacteria considered contaminants and the 35 
drawn from patients who had either died or been discharged by 
the time the culture became positive were excluded post randomi- 
sation, leaving 628 patients for the analysis ( Fig. 1 ). Among the 628 
samples, 421 (67.0%) were blood, 154 (24.5%) CSF, 46 (7.3%) peri- 
toneal fluid, 6 (1.0%) deep abscess samples, and 1 (0.2%) pleural 
fluid. 635 bacterial or fungal isolates were obtained (1 patient had 
4 isolates in a single culture and 4 patients had 2 isolates). There 
were 105 fungi, including Cryptococcus neoformans (63/635, 9.9%) 
and Talaromyces marneffei (36/635, 5.7%). There were no significant 
differences in baseline variables between the two arms ( Tables 1 
and 2 ). 
Primary outcome 
The proportion of patients who received optimal therapy within 
24 h, was not different between MALDITOF-MS (135/326, 41.4%) 
and control arms (120/302, 39.7%) (Adjusted Odds Ratio (AOR) 
1.17; 95% confidence interval (CI) 0.82–1.67, p = 0.40). In 9 cases 
(3 MALDITOF-MS, 6 control arm) the review committee recorded 
therapy as ‘unclassifiable’ and these were included in the ‘not opti- 
mal’ outcome as per the analysis plan. The predominant reason for 
the committee to consider a treatment non-optimal was because 
therapy was too broad (254/373, 68.1%) ( Table 3 ). 
Secondary outcomes 
There was no difference in the proportion of patients on op- 
timal therapy within 48 h of growth between MALDITOF-MS 
(151/326, 46.3%) and control arms (141/302, 46.7%, AOR 1.05 
p = 0.79) ( Table 4 ) or in the time from growth to optimal antimi- 
crobial therapy (HR 0.99 (95%CI 0.81– 1.22) p = 0.937) ( Fig. 2 ). 
There was no difference in the ordinal outcome (hospital out- 
come grouped into 5 categories - death, palliative discharge, 
survived with sequelae, transferred to another hospital and recov- 
ered) adjusted for site and sample type, between the MALDITOF- 
MS and control arms (AOR 0.869 (95%CI 0.65 – 1.16) p = 0.34). Al- 
though median hospital stay was the same for both arms, Cox pro- 
portionate hazards adjusted for site and specimen type demon- 
strated an increased hazard ratio for hospital discharge in the 
MALDITOF-MS arm ( Table 5 & Supplementary Fig. 2 ). Analysis 
in survivors only showed similar median length of stay in the 
MALDITOF-MS (15 days, IQR 11-21) and control arms (16 days, IQR 
11-23). There was no significant difference in other pre-specified 
secondary outcomes ( Table 5 and Supplementary Fig. 3). 
Subgroup analyses 
Limiting the analysis to the subgroup of patients with Gram- 
positive organisms cultured showed a trend towards an increased 
proportion on optimal therapy at 24 h in the MALDITOF-MS 
arm (45/103, 43.7%) compared to the control arm (41/111, 36.9%; 
p = 0.1). However, there was no significant effect observed in any 
pre-specified subgroup analysis ( Table 6 ). 
Exploratory analyses 
An analysis of mortality as a binary outcome (death or pal- 
liative discharge compared with all other outcomes) adjusted for 
B. Nadjm, V.Q. Dat and J.I. Campbell et al. / Journal of Infection 78 (2019) 454–460 457 
Table 1 
Baseline characteristics of groups by patients. 
N MALDITOF-MS n (% or IQR) N Control n (% or IQR) P ∗
Sex 326 302 0.45 
- Female 121 (37) 103 (34) 
Age (median years) 47 (32–59) 47 (35–58) 0.91 
Site 326 302 0.57 
- Ho Chi Minh city (HCMC) 187 (57) 180 (60) 
- Hanoi 139 (43) 122 (40) 
Source 325 302 0.58 
- Direct Admission 163 (50) 144 (48) 
- Hospital transfer 162 (50) 158 (52) 
Ward 326 302 0.41 
- Critical Care 79 (24) 82 (27) 
- Other 247 (76) 220 (73) 
Site of infection 326 302 0.33 
- Central nervous system (CNS) 81 (25) 89 (29) 
- Abdominal 83 (25) 81 (27) 
- Respiratory 31 (10) 23 (8) 
- Other 40 (12) 44 (15) 
- Unknown 91 (28) 65 (22) 
ICD-10 Code 325 302 0.12 
- Sepsis 87 (27) 81 (27) 
- HIV related 69 (21) 59 (20) 
- CNS Infection 46 (14) 49 (16) 
- Cirrhosis 28 (9) 29 (10) 
- Tetanus 6 (2) 4 (1) 
- Other 89 (27) 80 (27) 
Length of illness (median days) 321 6 (3–14) 300 6 (3–14) 0.62 
Time from sample collection to first growth (median hours) 34 (22–45) 36 (22–46) 0.41 
Time from sample collection to Gram stain (median hours) 287 31 (21–43) 267 33 (20–44) 0.63 
Specimen type 326 302 0.61 
- Blood Culture 222(68) 199 (66) 
- Other 104 (32) 103 (34) 
Pathogen type 326 302 0.40 
- Gram-positive 103 (32) 111 (37) 
Streptococcus suis 38 (12) 46 (15) 
-Gram-negative 167 (51) 137 (46) 
Escherichia coli 83 (25) 64 (21) 
- Fungi 52 (16) 52 (17) 
- Mixed 4 (1) 2 (1) 
∗ Fisher’s exact test for proportions and Kruskal–Wallis test for non-parametric data. 
Table 2 
Baseline characteristics by organisms isolated. 
N MALDITOF-MS n (%) N Control n (%) P ∗
Identification 329 306 
Gram-negative 
Total Enterobacteriaceae 131 (40) 104 (34) 0.15 
- Escherichia Coli 83 (25) 64 (21) 
- Klebsiella pneumoniae 29 (9) 21 (7) 
- Other Enterobacteriaceae 19 (6) 19 (6) 
Total Non- Enterobacteriaceae 40 (12) 36 (12) 0.98 
- Acinetobacter & Pseudomonas spp. 14 (4) 12 (4) 
- Other Gram-negatives 26 (8) 24 (8) 
Total Gram-positive 105 (32) 114 (37) 0.18 
- Streptococci 70 (21) 85 (28) 
- Staphylococcus aureus 32 (10) 26 (8) 
- Other Gram-positives 3 (1) 3 (1) 
Total Fungi 53 (16) 52 (17) 0.85 
- Cryptococcus neoformans 29 (9) 34 (11) 
- Talaromyces marneffei 20 (7) 16 (5) 
- Other fungi 4 (1) 2 (1) 
Bacteria resistance profiles (where tested) 
- S. aureus with methicillin resistance 32 16 (50) 26 15 (58) 0.99 
- Enterobacteriaceae with 3G-C resistance 131 63 (48) 103 a 50 (49) 1 
- Enterobacteriaceae with carbapenem resistance 123 b 9 (7) 97 c 1 1 0.06 
- Acinetobacter or Pseudomonas species with carbapenem resistance 13 d 5 (38) 11 e 5 (45) 1 
- Enterococci with vancomycin resistance 5 1 (20) 6 2 (33) 1 
∗ Fisher’s exact test.3G- C = 3rd generation cephalosporin. 
a 1 isolate not tested ( K. pneumoniae ). 
b 8 isolates not tested ( 1 Klebsiella pneumoniae , 7 Salmonella spp.). 
c 7 isolates not tested (2 E. coli , 2 K. pneumoniae , 3 Salmonella spp.). 
d 1 isolate not tested ( Acinetobacter sp. ). 
e 1 isolate not tested ( Acinetobater baumannii ). 
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Table 3 
Reasons for non-optimal therapy at 24 h after culture growth according to the independent re- 
view committee. 
MALDITOF-MS Control 
N = 191 N = 182 
n (%) n (%) 
Pathogen not covered 54 (28.3) 46 (25.3) 
Therapy too broad 130 (68.1) 122 (67) 
Therapy potentially effective but not ideal 3 (1.6) 6 (3.3) 
Growth of second pathogen within 48 h that was not covered 1 (0.5) 2 (1.1) 
No data 3 (1.6) 6 (3.3) 
Table 4 
Proportions of patients on optimal antibiotic therapy within 24 and 48 h of growth. 
N MALDITOF-MS n (%) N Control n (%) AOR (95% CI) a p 
Within 24 h 326 135 (41.4) 302 120 (39.7) 1.17 (0.82–1.67) 0.40 
Within 48 h 326 151 (46.3) 302 141 (46.7) 1.05 (0.74–1.50) 0.79 
a Adjusted odds ratio adjusted for specimen type (blood/other) and site. 
Table 5 
Pre-specified secondary outcomes. 
N MALDITOF-MS N Control P 
DDD of antimicrobial consumption from enrolment to discharge (median, IQR) 304 16.0 (8.4–33) 283 18.0 (9.0–39.3) 0.35 a 
Days of antimicrobial therapy from enrolment to discharge (median, IQR) 304 10 (6–15) 282 11 (7–17.8) 0.287 b 
Days in hospital (Median, IQR) 322 15 (10–21) 301 16 (10–23) 0.039 c 
Days spent in Critical Care (Median, IQR) 115 5 (2–11) 100 4 (3–10.3) 0.38 d 
Hours from first growth to pathogen identification (Median, IQR) 324 2.2 (1.7–28.1) 298 26.6 (24.7–48) ND 
Hours from sample collection to pathogen identification (Median, IQR) 324 43.2 (28.1–69.1) 298 66 (48–88.6) ND 
Days from sample collection to hospital discharge (Median, IQR) 326 11 (6.1–16.3) 302 12.3 (7.2–19) ND 
a Linear regression coefficient 0.92 (95% CI 0.78–1.09) after adjustment for site and specimen type. 
b Hazard ratio for stopping antibiotics 1.09 (95% CI 0.92–1.29) after adjustment for site and specimen type. 
c Hazard ratio for hospital discharge 1.18 (95% CI 1.01–1.38) after adjustment for site and specimen type. 
d Hazard ratio for ICU discharge 1.13 (95% CI 0.86–1.49) after adjustment for site and specimen type in those that had an ICU stayND statistical 
comparison not performed (as stipulated in the analysis plan). 
Table 6 
Pre-specified subgroup analyses of proportion of patients on optimal therapy within 24 and 48 h of culture growth in predefined subgroups. 
Proportion optimal within 24 h of culture growth Proportion optimal within 48 h of culture growth 
N MALDITOF n (%) N Control n (%) AOR (95% CI) a P N MALDITOF n (%) N Control n (%) AOR (95% CI) a P 
Sample Type 0.43 b 0.58 b 
- Blood 222 75 (33.8) 199 59 (29.6) 1.31 (0.84–2.07) 0.23 222 88 (39.6) 199 76 (38.2) 1.14 (0.73–1.78) 0.56 
- Other 104 60 (57.7) 103 61 (59.2) 0.96 (0.53–1.72) 0.88 104 63 (60.6) 103 65 (63.1) 0.91 (0.50–1.65) 0.75 
Site 0.60 b 0.98 b 
- HCMC 187 108 (57.8) 180 101 (56.1) 1.09 (0.72–1.67) 0.68 187 122 (65.2) 180 116 (64.4) 1.05 (0.68–1.62) 0.83 
- Hanoi 139 27 (19.4) 122 19 (15.6) 1.38 (0.71–2.74) 0.34 139 29 (20.9) 122 25 (20.5) 1.06 (0.57–1.99) 0.86 
Pathogen type 0.61 b 0.51 b 
- Gram-positive 103 45 (43.7) 111 41 (36.9) 1.74 (0.90–3.42) 0.10 103 47 (45.6) 111 47 (42.3) 1.42 (0.74–2.74) 0.30 
- Gram-negative 167 58 (34.7) 137 47 (34.3) 1.09 (0.65–1.82) 0.75 167 70 (41.9) 137 62 (45.3) 0.91 (0.55–1.52) 0.72 
- Fungi 52 31 (59.6) 52 32 (61.5) 1.09 (0.41–3.01) 0.86 52 33 (63.5) 52 32 (61.5) 1.38 (0.52–3.70) 0.53 
Admitted from 0.90 b 0.72 b 
- Home 163 71 (43.6) 144 61 (42.4) 1.17 (0.72–1.90) 0.53 163 80 (49.1) 144 71 (49.3) 1.10 (0.68–1.79) 0.70 
- Hospital 162 64 (39.5) 159 59 (37.3) 1.16 (0.68–1.99) 0.59 162 71 (43.8) 158 70 (44.3) 0.99 (0.58–1.69) 0.97 
Final diagnosis 0.73 b 0.76 b 
- Meningitis 76 57 (75.0) 65 48 (73.8) 1.28 (0.56–3.00) 0.56 76 59 (77.6) 65 51 (78.5) 1.11 (0.46–2.66) 0.81 
- Other 250 78 (31.2) 237 72 (30.4) 1.07 (0.71–1.63) 0.74 250 92 (36.8) 237 90 (38.0) 0.96 (0.64–1.45) 0.86 
a Adjusted for site and specimen type except where these are part of the subgroup. 
b Test for heterogeneity. 
site and sample type revealed no difference (MALDITOF-MS arm 
52/326 (16.0%), control arm 43/302 (14.2%), AOR 1.13 (95%CI 0.73–
1.76, p = 0.59)). 
Excluding outliers (the longest staying 1% of patients) in an 
analysis of hospital stay to explain the increased hazards ratio for 
hospital discharge in the MALDITOF-MS arm, the hazard ratio for 
discharge in the MALDITOF-MS arm dropped to 1.16 ( p = 0.067). 
An analysis to determine whether results were reaching the 
wards more quickly in the MALDITOF-MS arm demonstrated that 
the median time from growth to the pathogen identification re- 
port being received on the ward was 10.1 h (IQR 1.9 – 32.9 h) in 
the MALDITOF-MS arm and 31.0 h (IQR 27.4–54 h) in the control 
arm. 
A subgroup analysis of the 146 patients not on optimal ther- 
apy at the time of culture growth, that subsequently did receive 
optimal therapy, showed that the median time to optimal therapy 
was 2.0 (IQR 0.7–5.6) days in the MALDITOF-MS arm and 2.6 (IQR 
1.2 – 4.8) days in the control arm. A further subgroup analysis of 
those patients according to whether they were in critical care or 
not when cultures were drawn showed no significant difference in 
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both those in critical care (OR 0.90 (95% CI 0.5 – 1.72, p = 0.81)) or 
other wards (OR 1.16 (95%CI 0.79–1.69, p = 0.45)). 
An analysis looking at the proportion receiving antibiotic ther- 
apy at 24 h after culture growth that lacked in vitro activity against 
the isolated pathogen (inadequate therapy) showed little differ- 
ence between the two arms (54/326, 16.6% and 46/302, 15.2% in 
MALDITOF-MS and control arms respectively). 
Discussion 
Our study demonstrates that early identification of pathogens 
from cultures of blood and other sterile sites using MALDITOF-MS 
did not result in a difference in the proportion of patients on opti- 
mal therapy within 24 h of first growth. Neither did MALDITOF-MS 
alter the proportion on optimal therapy by 48 h, the time taken to 
provide optimal therapy, the duration or total antibiotic therapy, 
patient outcomes or time in intensive care. We found an associa- 
tion between MALDITOF-MS and earlier hospital discharge, but the 
significance was removed when outliers were excluded (very long 
stay patients) and we consider it unlikely to be clinically signifi- 
cant. Ours is not the first study to demonstrate that technological 
advances in rapid diagnostics, though compelling, do not always 
lead to improvements in clinically relevant outcomes in the ab- 
sence of an antibiotic stewardship programme. A similar result was 
found in a randomized study of the impact of peptide nucleic acid 
fluorescence in situ hybridisaton (PNA-FISH) on a variety of clinical 
outcomes in a tertiary care hospital in the USA. 19 
In common with previous studies, we found quicker pathogen 
identification and reporting. Our study gives some indication as to 
why MALDITOF-MS results did not result in improved outcomes. 
In both arms Gram stain results for positive blood cultures were 
available rapidly and possibly already provided sufficient informa- 
tion. The most common cause of suboptimal therapy was use of 
excessively broad therapies, suggesting that there were delays or 
reluctance in de-escalation of therapy. There was some evidence 
that the intervention was more successful in patients with Gram- 
positive infections. This may relate to identifying Streptococcus suis , 
a common cause of both meningitis and severe sepsis which has as 
yet not evolved reduced susceptibility to penicillin 20 and exclusion 
of alternative pathogens. 
One other trial of MALDITOF-MS compared with conventional 
microbiology with 28 day mortality as the primary endpoint has 
completed recruitment in the UK but has yet to be reported (the 
RAPIDO trial, https://doi.org/10.1186/ISRCTN97107018 ). While other 
studies have established that MALDITOF-MS can identify pathogens 
in the tropics, 21 all eight publications that explored the clinical im- 
pact of MALDITOF-MS 13 –18 , 22 , 23 were conducted in high income 
countries (HICs). Three explored the impact of MALDITOF-MS com- 
pared with conventional diagnostics 15 , 16 , 22 without an ASP compo- 
nent. One was restricted to peritoneal dialysis fluid, 16 the others 
recruited patients with bloodstream infections. 15 , 22 One showed a 
significant improvement in the proportion with appropriate ther- 
apy within 24 h of growth (from 64% to 75.3%, p = 0.01), 15 while 
the other found a non-significant improvement in the proportion 
receiving active treatments within 48 h of blood cultures being 
(from 89.8% to 95.6%, p = 0.09). 22 Five studies examined the impact 
of MALDITOF-MS plus ASP with conventional diagnostics without 
ASP. 13 , 14 , 17 , 18 , 23 These studies all showed improvements in time to 
active or appropriate therapy and two showed lower mortality. 13 , 14 
Our study has the advantage of addressing the single interven- 
tion of MALDITOF-MS, highlighting the need to investigate addi- 
tional supports, such as ASP, to achieve clinical impact. It cannot 
be generalized to settings where ASP are already in place. The in- 
dividually randomised nature of the study is robust but this design 
may not account for changes in prescribing that could arise from 
a ‘cultural shift’ resultant from a wholesale change in diagnostic 
practice. Although the use of two sites and the large sample size is 
a strength, the use of specialist infectious diseases hospitals could 
cause bias and poor generalisability. However, it seems unlikely 
that MALDITOF-MS alone would be more effective at changing pre- 
scribing practice in a setting where staff are less experienced in 
managing infection and the uniformity of the results across differ- 
ent pathogen groups makes it unlikely that the case mix seen is 
responsible for the negative results. There may be criticism over 
the subjectivity of the primary endpoint (optimal therapy as deter- 
mined by a panel of experts) and others have utilized spectrum-of- 
activity scores to demonstrate improvements in de-escalation. 24 , 25 
However, the blinded nature of the committee, and the use of a 
single committee for all evaluations, should have minimized bias. 
Additionally, the absence of benefit in the comparison of the pro- 
portion receiving inadequate therapy in the two arms at 24 h sug- 
gests that the findings were real. We did not collect data on pa- 
tient severity (SOFA/APACHE II scores), making it difficult to assess 
whether a subgroup of either more or less severe patients may 
have seen benefit from the intervention. However an exploratory 
analysis showed no effect of the intervention in patients that were 
in critical care at the time cultures were drawn. Our study did not 
achieve the prespecified sample size. However, this large sample 
size was determined to accurately assess if the intervention was 
effective for blood cultures in each hospital, we surpassed the sam- 
ple size necessary for the primary outcome and it is thus unlikely 
we missed a relevant positive result. Our setting has particularly 
high proportions of antibiotic resistant organisms, and results may 
not be generalisable to settings where these are lower. Although 
the contamination rate was noted to be high during the study, it is 
not outside that reported in the literature. 26 Attempts were made 
to reduce the contamination rate through additional education for 
those responsible for venepuncture, and replacement of liquid dis- 
infection fluids with disposable sterile alcohol wipes. There was 
a small number of cases where the endpoint review committee 
was unable to reach a decision (6 in the control arm and 3 in the 
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MALDITOF-MS arm), these results could not have changed the re- 
sult of the primary outcome (data not shown). 
Despite these negative findings there are several positive as- 
pects to MALDITOF-MS that should not be overlooked. Firstly, even 
speedier identification can be achieved by both processing samples 
direct from blood culture 27 (without the subculture onto blood 
agar) and by running the machine more frequently than twice 
daily. However, this requires changes to work flow that were not 
possible within the trial and, based on the results we obtained, 
would be unlikely to have had an impact on the results. Rapid 
AST, either through short incubation with antibiotics or through 
analysis of the spectra obtained, has also now been described us- 
ing MALDITOF-MS. 28 Though more technically difficult, such re- 
sults may have been more compelling in this setting and warrant 
further evaluation. 
In conclusion, our study showed no improvement in antimi- 
crobial prescribing or other patient or provider centred outcomes 
through MALDITOF-MS, though MALDITOF-MS did produce results 
rapidly in our setting. While MALDITOF-MS has many other com- 
pelling advantages, our findings suggest that it is unlikely to lead 
to improvements in prescribing on its own. Further studies in this 
setting exploring the addition of ASPs, and education of the diag- 
nostic and prescribing workforce would be useful. 
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